Lilly Files for Approval of Once-Weekly Prozac. Faced with declining sales from competing SSRIs, and the looming expiration of its patent rights in 2003, this is one of several slightly different formulations of fluoxetine (Prozac), the first of the new generation of antidepressants, that Eli Lilly proposes to market.